Skip to main content

Month: February 2021

KITRON – Key information relating to the cash dividend to be paid by Kitron ASA

Written by Customer Service on . Posted in Public Companies.

Tranche 2 of 2* Dividend amount: NOK 0.35 per share* Declared currency: NOK* Last day including right: 4 October 2021* Ex-date: 5 October 2021* Record date: 6 October 2021* Payment date: On or about 22 October 2021* Date of approval: 21 April 2021This information is published in accordance with the requirements of the Oslo Børs Continuing Obligations for stock exchange listed companies. 

Continue reading

KITRON – Nøkkelinformasjon knyttet til foreslått kontantutbytte for Kitron ASA

Written by Customer Service on . Posted in Public Companies.

Transje 2 of 2* Utbyttebeløp: NOK 0,35 per aksje* Annonsert valuta: NOK* Siste dag inklusive: 4. oktober 2021* Ex-dato: 5. oktober 2021* Record date (eierregistreringsdato): 6. oktober 2021* Betalingsdato: På eller rundt 22. oktober 2021* Vedtaksdato: 21. april 2021Denne informasjonen offentliggjøres i henhold til kravene i Oslo Børs løpende forpliktelser for børsnoterte selskaper. 

Continue reading

Corporate governance statement and Remuneration report for 2020 available

Written by Customer Service on . Posted in Public Companies.

Uponor Corporation     Stock exchange release     11 February 2021     08:15 EETCorporate governance statement and Remuneration report for 2020 availableUponor Corporation’s Corporate governance statement and Remuneration report for 2020 have been published. The statements are attached to this release and can also be found on the company’s investor website at investors.uponor.com.Uponor CorporationSusanna InkinenVice President, Communications and Corporate ResponsibilityTel. +358 20 129 2081DISTRIBUTION:Nasdaq HelsinkiMediawww.investors.uponor.comUponor in briefUponor is rethinking water for future generations. Our offering, including safe drinking water delivery, energy-efficient radiant heating and cooling and reliable infrastructure, enables a more sustainable living environment. We help our customers in residential and commercial...

Continue reading

Selvitys hallinto- ja ohjausjärjestelmästä sekä palkitsemisraportti 2020

Written by Customer Service on . Posted in Public Companies.

Uponor Oyj     Pörssitiedote     11.2.2021     8.15Selvitys hallinto- ja ohjausjärjestelmästä sekä palkitsemisraportti 2020Uponor Oyj:n selvitys hallinto- ja ohjausjärjestelmästä sekä palkitsemisraportti vuodesta 2020 on julkaistu. Selvitykset ovat tämän tiedotteen liitteenä ja ovat luettavissa myös yhtiön sijoittajasivuilla osoitteessa sijoittajat.uponor.fi.Uponor OyjSusanna InkinenViestintä- ja yritysvastuujohtajaPuh. 020 129 2081JAKELU:Nasdaq HelsinkiTiedotusvälineetwww.sijoittajat.uponor.fi  Uponor lyhyestiUponor kehittää veteen liittyviä ratkaisuja tulevien sukupolvien parhaaksi. Tuotteemme ja palvelumme turvalliseen vedenjakeluun, energiatehokkaaseen lämmitykseen ja viilennykseen sekä luotettavaan yhdyskuntatekniikkaan mahdollistavat kestävämmän elinympäristön. Autamme asiakkaitamme asunto-, liike- ja julkisessa rakentamisessa, teollisuudessa, kunnissa...

Continue reading

KITRON – Key information relating to the cash dividend to be paid by Kitron ASA

Written by Customer Service on . Posted in Public Companies.

Tranche 1 of 2* Dividend amount: NOK 0.35 per share* Declared currency: NOK* Last day including right: 21 April 2021* Ex-date: 22 April 2021* Record date: 23 April 2021* Payment date: On or about 3 May 2021* Date of approval: 21 April 2021This information is published in accordance with the requirements of the Oslo Børs Continuing Obligations for stock exchange listed companies. 

Continue reading

KITRON – Nøkkelinformasjon knyttet til foreslått kontantutbytte for Kitron ASA

Written by Customer Service on . Posted in Public Companies.

Transje 1 of 2* Utbyttebeløp: NOK 0,35 per aksje* Annonsert valuta: NOK* Siste dag inklusive: 21. april 2021* Ex-dato: 22. april 2021* Record date (eierregistreringsdato): 23. april 2021* Betalingsdato: På eller rundt 3. mai 2021* Vedtaksdato: 21. april 2021Denne informasjonen offentliggjøres i henhold til kravene i Oslo Børs løpende forpliktelser for børsnoterte selskaper. 

Continue reading

Basilea achieves preclinical milestone in oncology collaboration on potential first-in-class kinase inhibitor

Written by Customer Service on . Posted in Public Companies.

Basel, Switzerland, February 11, 2021Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has promoted a potential first-in-class small-molecule kinase inhibitor from its research portfolio into the next preclinical development stage, which triggers an undisclosed milestone payment to its external partner. Basilea is planning to start preclinical studies with the goal of filing for an IND, i.e. the authorization to evaluate the drug candidate in phase 1 clinical studies, by the end of this year.Dr. Laurenz Kellenberger, Chief Scientific Officer, said: “We are pleased with reaching this important preclinical milestone in our external collaboration. The kinase inhibitor fits perfectly with our oncology R&D strategy. Its mode of action and unique kinase inhibition profile offer the possibility for differentiation and targeted...

Continue reading

Basilea erreicht präklinischen Meilenstein im Rahmen einer Kooperation zur Entwicklung eines potenziellen First-in-Class Kinase-Inhibitors für die Krebstherapie

Written by Customer Service on . Posted in Public Companies.

Basel, 11. Februar 2021Basilea Pharmaceutica AG (SIX: BSLN) gab heute bekannt, dass sie einen niedermolekularen Kinase-Inhibitor und potenziellen First-in-Class-Wirkstoff aus ihrem Forschungsportfolio in die nächste präklinische Entwicklungsstufe überführt hat, was eine Meilensteinzahlung in nicht genannter Höhe an ihren externen Kooperationspartner auslöst. Basilea plant nun den Beginn präklinischer Studien mit dem Ziel, bis Ende dieses Jahres einen IND-Antrag (Investigational New Drug Application) zu stellen, d.h. die Genehmigung zur Durchführung von klinischen Phase-1-Studien mit dem Medikamentenkandidaten zu beantragen.Dr. Laurenz Kellenberger, Chief Scientific Officer, sagte: „Wir freuen uns über das Erreichen dieses wichtigen präklinischen Meilensteins in unserer externen Kooperation. Der Kinase-Inhibitor passt perfekt zu unserer...

Continue reading

Huhtamäki Oyj’s Results January 1–December 31, 2020: Solid performance despite COVID-19 pandemic

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

HUHTAMÄKI OYJ FINANCIAL STATEMENT RELEASE 11.2.2021 AT 8:30Huhtamäki Oyj’s Results January 1–December 31, 2020: Solid performance despite COVID-19 pandemicQ4 2020 in brief     Net sales decreased 7% to EUR 813 million (EUR 875 million)     Adjusted EBIT was EUR 73 million (EUR 75 million); reported EBIT was EUR 48 million (EUR 72 million)     Adjusted EPS was EUR 0.48 (EUR 0.48); reported EPS was EUR 0.30 (EUR 0.46)     Comparable net sales growth was -2% at Group level and -7% in emerging markets     The impact of currency movements was EUR -52 million on the Group’s net sales and EUR -5 million on EBITQ1-Q4 2020 in brief     Net sales decreased 3% to EUR 3,302 million (EUR 3,399 million)     Adjusted EBIT was EUR 302 million (EUR 293 million); reported EBIT was EUR 265 million (EUR 286 million)     Adjusted EPS was EUR 1.95 (EUR 1.88)...

Continue reading

Huhtamäki Oyj:n tilinpäätöstiedote 1.1.–31.12.2020: Vakaata kehitystä koronapandemiasta huolimatta

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

HUHTAMÄKI OYJ TILINPÄÄTÖSTIEDOTE 11.2.2021 KLO 8.30Huhtamäki Oyj:n tilinpäätöstiedote 1.1.–31.12.2020: Vakaata kehitystä koronapandemiasta huolimattaQ4 2020 lyhyesti     Liikevaihto laski 7 % 813 milj. euroon (875 milj. euroa)     Oikaistu liikevoitto oli 73 milj. euroa (75 milj. euroa); raportoitu liikevoitto 48 milj. euroa (72 milj. euroa)     Oikaistu osakekohtainen tulos oli 0,48 euroa (0,48 euroa); raportoitu osakekohtainen tulos 0,30 euroa (0,46 euroa)     Liikevaihdon vertailukelpoinen kasvu oli konsernitasolla -2 % ja kehittyvillä markkinoilla -7 %     Valuuttakurssien vaihtelujen vaikutus oli konsernin liikevaihtoon -52 milj. euroa ja liikevoittoon -5 milj. euroaQ1-Q4 2020 lyhyesti     Liikevaihto laski 3 % 3 302 milj. euroon (3 399 milj. euroa)     Oikaistu liikevoitto oli 302 milj. euroa (293 milj. euroa); raportoitu liikevoitto...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.